03.03.2015 • NewsDede WillamsPharmaceuticalsSanofi

New Sanofi Chief’s “Welcome Bonus” Slammed

French pharmaceuticals producer group Sanofi has come under fire from French government ministers over a welcome bonus planned for its new CEO.

Olivier Brandicourt, who moves to Sanofi from Bayer at the beginning of April, could pocket a one-off "golden handshake" of €4 million on top of his salary of €4.2 million euros a year.

A spokesman for the French government called the package "incomprehensible." Sanofi is France's largest publicly listed drugmaker.

The company said the former physician would be paid a fixed salary of €1.2 million a year in addition to a performance-related amount targeted at 150% of that, with a cap at 250%. He also would get stock options and performance shares.

Brandicourt's €4 million golden handshake on top of that was billed as compensation for loss of benefits at Bayer and will be split between 2 million when he starts in April and the rest in January 2016 if he is still in the job.

Executive pay is frequently a touchy subject in France, even at investor-controlled companies like Sanofi, where the government has no direct say in pay packages. The Socialist government has set limits on executive pay for public sector companies.

"Drugs are reimbursed by taxpayers, so it's all of the French people who pay into the health system and reimburse drugs who are going to pay the golden handshake," senior government minister Segolene Royal said in a TV interview.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.